Janssen Biotech Inc.

09/15/2024 | Press release | Distributed by Public on 09/15/2024 06:26

New data from TAR 200 Phase 2b SunRISe 1 study show 84 percent complete response rate in patients with high risk non muscle invasive bladder cancer